As reported in the New England Journal of Medicine, “This trial of aspirin for the primary prevention of cardiovascular disease demonstrates a conclusive reduction in the risk of myocardial infarction...As reported in the New England Journal of Medicine, “This trial of aspirin for the primary prevention of cardiovascular disease demonstrates a conclusive reduction in the risk of myocardial infarction (heart attack).” (Source: “Final Report on the Aspirin Component of the Ongoing Physicians’ Health Study,” New England Journal of Medicine 321(3):129–35, 1989.) In the preceding example, we compared the difference in risk (how much the risk changed) to the risk for the placebo (nontreatment) group:
